

An easy 3D printing approach to manufacture Vertical Diffusion Cells for *in vitro* release and permeation studies

Mattia Tiboni¹, Giulia Curzi², Annalisa Aluigi³ and Luca Casettari^{1*}

¹*Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento, 6, 61029 Urbino (PU), Italy*

²*Prosopika srl, Via Fano, 1/1, 61036 Colli al Metauro (PU), Italy*

³*Institute of Organic Synthesis and Photoreactivity e Italian National Research Council, Via P. Gobetti, 101, 40129, Bologna, Italy*

ABSTRACT

Vertical diffusion cells are utilized in the pharmaceutical and cosmetic fields to study the release and permeation of active ingredients through polymeric or biological membranes. Nevertheless, the commercially available glass-based systems are expensive and need to be carefully handled due to their fragility. Fusion deposition modeling 3D printing is an additive manufacturing technique that allows producing objects by printing layer over layer different thermoplastic materials. Among them, polypropylene is a robust, flexible, and chemically inert polymer that can resist to many organic solvents and to heating. In this work, we designed and printed a vertical diffusion cell following pharmacopeia requirements by using polypropylene in a fused deposition modeling 3D printer. The model was developed to fit in a heating block to avoid the use of warm water recirculating system. The vertical diffusion cells were leak-free and presented chemical resistance and no interaction with the tested molecules (*i.e.*, caffeine, diclofenac sodium, and glycyrrhetic acid). The 3D printed cells were compared to commercially available glass cells and then two different types of synthetic membranes (*i.e.*, PDMS and Strat-M[®]) were used to evaluate the permeation of a caffeine hydrogel. The developed 3D printed testing system could represent an efficient alternative to the glass-based equipment.

Keywords: 3DP; fusion deposition modeling (FDM); Franz cells; VDCs; polypropylene (PP); polymeric membranes.

32 1. INTRODUCTION

33 During the last few years, 3D printing (3DP) continued to grow as an innovative additive
34 manufacturing (AM) technology with applications in many different areas including pharma
35 (Melocchi et al., 2020; Ngo et al., 2018). Recently, many pharmaceutical applications have been
36 published in the literature reporting the production of dosage forms (i.e., tablets, capsules,
37 suppositories, and vaginal rings), testing systems (i.e., ocular, nasal, and respiratory models), and
38 manufacturing devices (i.e., microfluidic chips) (Lim et al., 2018; Mathew et al., 2020; Tiboni et al.,
39 2020; Trenfield et al., 2020). Among the 3D printing techniques, fused deposition modeling (FDM)
40 presents several advantages including relatively inexpensive printers and materials, low maintenance
41 costs, a large selection of commercially available materials, the ease of initial use, and the ability to
42 start, stop, and integrate complexity on the fly (Romanov et al., 2018).

43 Taking advantage of this technology, the acronym DIY (Do-It-Yourself) is gaining attention over
44 research laboratories. The additive manufacturing techniques allow researchers to develop and
45 produce almost any kind of object needed in the laboratory from the simplest to even more complex
46 ones with a real decrease in costs (Boparai et al., 2016; Capel et al., 2018).

47 In the pharmaceutical and cosmetic fields, vertical diffusion cells (VDCs or Franz cells) are routinely
48 used for the study and analysis of both release and permeation of active molecules from different
49 formulations through the use of polymeric and biological membrane (Marques et al., 2009). These
50 kinds of studies are important since they can determine the feasibility of delivering the cargo to and
51 through the skin (Johal et al., 2016).

52 Conventional VDCs are typically manufactured from glass and they can be found in the market in
53 many shapes, sizes and may be modified depending on the required experimental conditions.
54 According to United States Pharmacopeia (USP, www.uspnf.com, Topical and transdermal drug
55 products), the VDC assembly consists of two chambers (donor and receptor), separated by a
56 membrane. Commonly, this system is used for testing the *in vitro* release rate of topical drug products
57 such as creams, gels, and ointments. Even alternative diffusion cells that conform to the same general
58 design can be used and can be made from any materials that do not react with or absorb the test
59 product or samples. Commercial VDCs are commonly made from borosilicate glass that results
60 fragile and require careful handling during their utilization.

61 Only one 3D printing approach was considered in the literature to produce VDCs using
62 stereolithography (SLA) (Sil et al., 2020). This additive manufacturing technique requires the
63 utilization of acrylate-based resins which are photopolymerized during the printing procedure and
64 then they need to be post-cured to obtain the final object. Moreover, the type of resin utilized

65 presented physical and chemical interactions with the tested drug, requiring a plastic coating to avoid
66 these problems.

67 FDM, in comparison to SLA, is easier to use, it has lower overall production costs and it does not
68 need post-curing after printing. Another important aspect to consider is that the selection of
69 thermoplastic FDM printing materials is very wide and the most appropriate one can be chosen
70 depending on the needs.

71 In this work, we developed an alternative 3DP vertical diffusion cell using polypropylene (PP) as
72 manufacturing material in a FDM printer. This material was selected since it is a robust, flexible, and
73 chemically inert polymer that can resist to many organic solvents and to heating (Price et al., 2020).
74 The 3DP VDCs were tested for leaking and then were compared to glass VDCs to evaluate the
75 potential applicability.

76 In the *in vitro* permeability studies, different membranes can be used including human skin, animal
77 skin as well as polymeric membranes. However, biological membranes have limitations such as cost
78 and availability of human skin and ethical consideration for the use of animal skins. Besides,
79 compared to synthetic membranes, biological models exhibit high variability that complicates the
80 experimental design, statistical significance, and number of replicates required (Haq et al., 2018a).
81 Moreover, biological models possess a short half-life, special storage requirements, higher costs, and
82 safety issues (Haq et al., 2018b).

83 For our work, we selected skin-mimicking membranes (Strat-M[®]) which comprise two layers of
84 polyethersulfone on top of one layer of polyolefine. These membranes possess a porous structure that
85 imparts additional skin-like properties by creating a gradient across the entire thickness (Uchida et
86 al., 2015).

87 Finally, Strat-M[®] membranes were compared with polydimethylsiloxane (PDMS) membranes (Ng et
88 al., 2012), using a caffeine hydrogel as model formulation since this active is a hydrophilic molecule
89 widely used in topical applications (Herman and Herman, 2012).

90

91 **2. MATERIALS AND METHODS**

92 **2.1 Materials**

93 Neutral polypropylene 3D printing filament was kindly provided from Verbatim (Italy). Caffeine was
94 kindly provided by BASF (Germany), diclofenac sodium was obtained from Farmalabor (Italy),
95 glycyrrhethinic acid, and xanthan gum were purchased from A.C.E.F. (Italy). Strat-M[®] membranes
96 were obtained from Merck (Germany), 250 µm thick polydimethylsiloxane (PDMS) membranes were
97 kindly provided by Shielding Solutions Limited (Essex, UK), Spectra/Por[™] 7 Standard RC dialysis

98 membranes (6-8 kDa cut-off) were purchased by Spectrum Labs (USA). All the other solvents used
99 were HPLC grade.

100

101 **2.2 Design and development of the VDCs**

102 The original 3D model project was designed using the free online computer aided design (CAD) tool
103 Tinkercad® (Autodesk, USA). The cell was designed to fit in a heating block (IKA, Germany) used
104 to control the temperature during experiments. The cell is composed of a receptor part in which is
105 present a withdrawal window with its cap, two donor compartments depending on the origin of the
106 formulation, liquid or semisolid, and a stirring block useful to adjust the receptor volume. The 3D
107 printed stirring block presents a slot to insert a magnetic stirring bar. The 3DP VDCs present a
108 receptor compartment volume of 9 or 11.5 mL (with or without stirring block respectively) and an
109 effective diffusion area of 1.583 cm². The files were exported from the online CAD software as STL
110 (Stereolithography interface format) to be then converted into machine language with a computer
111 aided manufacturing (CAM) software (STL files provided in the supplementary material).

112

113 **2.3 Manufacturing process of the 3D printed VDCs**

114 3D-printed PP VDCs were produced via fused deposition modeling (FDM) using an Ultimaker 3
115 printer (Ultimaker, The Netherlands). The VDCs were printed at a print speed of 25 mm/s with a
116 nozzle temperature of 205 °C. The infill density was set at 100 % and the build plate was preheated
117 at 85 °C after the application of a polypropylene adhesion sheet (Ultimaker, The Netherland). The
118 original STL file was converted to a print pattern using Ultimaker Cura 4.7 software (Ultimaker, The
119 Netherlands). Layer thickness was set to 150 µm enabling the production of leak-free PP VDCs. The
120 3DP VDCs were tested for leaks by filling both compartments with water. The receptor compartment
121 and the donor compartment were ulteriorly sealed with the application of laboratory sealing film. The
122 system was examined for leaks over a minimum of 24 hours and it was considered good if no water
123 was present on the outer wall after this period.

124

125 **2.4 Compatibility studies of the 3D printed VDCs**

126 To assess the compatibility of the VDCs with active compounds, three different model drugs were
127 evaluated, *i.e.*, caffeine (2 mg/mL water solution), diclofenac sodium (2 mg/mL water solution),
128 glycyrrhethinic acid (0.02 mg/mL 50% ethanolic solution). The solutions were prepared and used to
129 fill the receptor compartment of the cell that was then closed using laboratory sealing film and
130 warmed up at 32 °C together with 400 rpm magnetic stirring. After 24 hours, the concentration in the

131 receptor compartment was compared with the initial concentration to confirm that any amount of
132 drug was retained or adsorbed from the cell wall.

133 The amounts of the model drugs were measured by HPLC (1260 Infinity II, Agilent, USA) using a
134 mixture of 0.5% formic acid in water and methanol (ratio 60:40 for caffeine, 30:70 for diclofenac
135 sodium, and 5:95 for glycyrrhetic acid) as mobile phase, with a flow rate of 1 mL/min in an Agilent
136 Zorbax Eclipse Plus C18, 150 x 4.6 mm, 5 μ m column (Agilent, USA). The injection volume was 20
137 μ L and the detection signals were recorded at 275 nm (caffeine and diclofenac sodium) and 276 nm
138 (glycyrrhetic acid) keeping the analysis system at room temperature.

139

140 **2.5 *In vitro* release comparison: glass vs polypropylene 3D printed VDCs using a caffeine** 141 **hydrogel**

142 A comparison between commercial glass VDCs and 3DP VDCs was performed using a cellulose-
143 based dialysis membrane (6-8 kDa cut-off, Spectra/Por 7 Standard RC Dry Dialysis Tubing,
144 Spectrum Labs, USA). The selected model formulation was a caffeine hydrogel composed of caffeine
145 (5 mg/mL), xanthan gum (0.5% w/v), and water.

146 The glass VDCs (Teledyne Hanson Research, USA) presented a receptor compartment volume of 7
147 mL and an effective diffusion area of 1.766 cm² meanwhile the 3DP VDCs were utilized with the
148 stirring block presenting a receptor volume of 9 mL and an effective diffusion area of 1.583 cm².
149 Water was used as receptor medium in both cell types. The receptor medium was continuously stirred
150 at 400 rpm. The glass system was thermostated at 32 \pm 1 $^{\circ}$ C with a circulating jacket meanwhile the
151 3DP system was thermostated at 32 \pm 1 $^{\circ}$ C with a heating block positioned over a heating plate. The
152 efficacy of heat transfer and temperature control between the heating plate and the receptor medium
153 inside the 3DP cell was previously assessed by measuring the temperature with a thermometer. At
154 predetermined sampling intervals (0.5, 1, 2, 3, 4, 5, 6, and 24 h), samples were withdrawn from the
155 receptor compartment and replaced with an equal volume (0.2 mL) of fresh buffer. The content of
156 the active compound in each sample was then determined by HPLC as reported above. A calibration
157 curve of caffeine was performed with a concentration ranging from 0.01 to 0.5 mg/mL obtaining a
158 correlation coefficient (R²) of 0.9997.

159 The amounts of the active compound released at each time point (AR_n) were obtained using the eq.
160 (1) for the first time point and eq. (2) for the subsequent time points:

161

$$162 \quad AR_{t_1} = \frac{C_{t_1} * 1000 * V_c}{A_o} \quad (1)$$

163

164
$$AR_{t_n} = \frac{C_{t_n} * 1000 * V_c}{A_o} + (AR_{t_{n-1}} * \frac{V_s}{V_c}) \quad (2)$$

165

166 where AR ($\mu\text{g}/\text{cm}^2$) is the amount released at t_n sampling interval, the C_t (mg/mL) is the concentration
167 of caffeine determined at t_n sampling interval, V_c (mL) is the volume of diffusion cell receptor
168 compartment, A_o (cm^2) is the cell diffusion area and V_s (0.2 mL) is the sampling aliquot volume.

169

170 **2.6 *In vitro* permeation studies using 3D printed VDCs with different membrane models**

171 Permeation studies using the PP 3DP VDCs were conducted using a caffeine hydrogel (5 mg/mL,
172 0.5% xanthan gum) applied to two different membranes, *i.e.*, skin mimicking Strat-M[®] membranes
173 and 250 μm thick PDMS membranes. The skin-mimicking Strat-M[®] membranes are composed of
174 two layers of polyethersulfone on top of one layer of polyolefine. These polymeric layers create a
175 porous structure with a gradient across the membrane in terms of pore size and diffusivity. The porous
176 structure is impregnated with a proprietary blend of synthetic lipids, imparting additional skin-like
177 properties to the synthetic membrane (Kaur et al., 2018). PDMS membranes were selected as model
178 membranes, already used in other studies, with a lower permeation compared to dialysis membranes
179 (Ilbasmiş Tamer and Değim, 2007; Jung et al., 2012; Sil et al., 2020).

180 The receptor chambers were filled with water kept continuously stirred at 400 rpm. The system was
181 thermostated at 32 ± 1 °C with a heating block positioned over a heating plate. At predetermined
182 sampling intervals (0.5, 1, 2, 3, 4, 5, 6, 24 h), samples were withdrawn from the receptor compartment
183 and replaced with an equal volume (0.2 mL) of water. The content of caffeine in each sample was
184 determined by HPLC with the method reported above. Equations 1 and 2 were utilized to calculate
185 the amount of active compound released at each time point.

186

187 **2.7 Statistics**

188 The data presented are the mean \pm standard deviation of triplicate measurements and are
189 representative of at least three independent experiments.

190


191 **3. RESULTS AND DISCUSSION**

192

193 **3.1 Design, 3D printing, and compatibility studies of the vertical diffusion cells (VDCs)**

194 The CAD design of the 3DP VDCs was developed following the USP guidelines presenting a receptor
195 and a donor compartment (Figure 1).

196



197

198 **Figure 1.** CAD design of the VDC parts and polypropylene 3D printed parts. A) Receptor compartment with withdrawal
199 window; B) Stirring block; C) Cap for donor compartment for liquid formulations; D) Cap for withdrawal window; E)
200 Donor compartment for semisolid formulations; F) Donor compartment for liquid formulations.

201

202 These two sections are separated by a membrane (*e.g.*, synthetic or biological) that allows the
203 permeation of the tested molecule. The material selected to print out the entire system was
204 polypropylene since it is a robust, flexible, and chemically inert polymer.

205 This last property is the most important to meet the pharmacopeia requirements since the cell material
206 does not have to interact chemically and/or physically with the compound analyzed. This is also the
207 reason because VDCs are traditionally made from glass that is a material known for its lack of
208 interaction with active ingredients (Skelly et al., 1987). The drawbacks of this material are mainly its
209 fragility and the high production costs. Taking advantage of FDM 3D printing, it was possible to print
210 a VDC with a low cost and without fragility since PP results robust and flexible. The printed cell
211 resulted semitransparent with the possibility to examine the receptor medium for the presence of air
212 bubbles. The printed layers fusion was evaluated to prevent eventual leakage. The receptor and the
213 donor compartments were filled to the top with water and sealed with laboratory film. After 24 hours
214 no leakages were detected from the VDCs confirming the effective fusion of the layers produced with
215 the FDM technique.

216 Then, another important step was to evaluate the compatibility of the material with active molecules
217 even if PP is already known for its chemical resistance. Authors were more worried about eventual
218 physical absorption into spaces between layers. We tested three different molecules varying their


219 chemical nature: caffeine was selected as amphiphilic molecule, diclofenac sodium as salt, and
220 glycyrrhetic acid as hydrophobic molecule. These molecules in their respective solutions were used
221 to fill the receptor compartment for 24 hours and the analysis of concentration after this period
222 showed no differences with the initial concentration confirming the compatibility with these active
223 molecules. As it is impossible to test every type of molecule, we choose these three as models, but
224 we suggest assessing the compatibility of each specific active compounds before utilizing it in an *in*
225 *vitro* permeation test with the 3D printed VDCs.

226

227 3.2 *In vitro* release and permeation studies

228 *In vitro* release studies were performed first in both glass and 3DP VDCs to evaluate effective
229 comparability between the two systems. A commonly used cellulose dialysis membrane was applied
230 to divide the receptor from the donor compartment and a caffeine hydrogel was utilized. This
231 comparison showed no significant differences in the release of the active molecule with the 3DP
232 VDCs when compared with the glass VDCs as shown in figure 2 confirming the suitability of the
233 developed 3DP system. Release studies with the 3DP VDCs resulted in $1164 \pm 36 \mu\text{g}/\text{cm}^2$ of caffeine
234 permeated in the receptor compartment after 24 h meanwhile the release was $1123 \pm 41 \mu\text{g}/\text{cm}^2$ for
235 the glass homologues.

236



237


238 **Figure 2.** Comparison between glass VDCs and the 3DP VDCs using a cellulose dialysis membrane (6-8 kDa cut-off)
239 and a 5 mg/mL caffeine hydrogel.

240

241 After the assessed suitability of the 3DP VDCs, two different membranes were employed for a
242 permeation study using a caffeine hydrogel. Excised human and animal skins are often utilized to
243 study skin permeation profiles of topical formulations, however, they are expensive and possess
244 several drawbacks. Among them, there are variations of skin thickness, diseased skin states,
245 preparation complexity, age of the donor, the density of hair follicles, and skin storage conditions that
246 can hinder reproducibility data (Haq et al., 2018b, 2018a).

247 In this study, we decided to compare standardized synthetic Strat-M[®] membranes as a reproducible
248 alternative to excised human skin (Haq et al., 2018a) and 250 μm thick PDMS membranes as a low
249 permeability model membranes (Figure 3) (Ng et al., 2010).

250



251

252 **Figure 3.** Comparison between Strat-M[®] and PDMS membranes using the 3DP VDCs and a 5 mg/mL caffeine hydrogel.

253

254 The drug permeation resulted higher with the Strat-M[®] membranes with an amount permeated after
255 24 h of $215 \pm 18 \mu\text{g}/\text{cm}^2$ meanwhile for the PDMS membranes, the drug permeated was more than 4
256 times lower ($44.6 \pm 2.6 \mu\text{g}/\text{cm}^2$). Since this membrane is made with a hydrophobic material, the
257 permeation through it is influenced by the nature of the tested molecule. Since caffeine result
258 hydrophilic, its passage through this type of membrane resulted very low even after 24 hours.

259 In release studies, mathematical models play a crucial role in evaluating the drug release mechanism
260 (Siepmann and Peppas, 2011). In these studies, the release profile of the drug from the xanthan gum
261 hydrogel resulted linear with the time for the utilized membranes confirming zero-order kinetics
262 (Strat-M[®] R^2 0.9972; PDMS R^2 0.9974) (César dos Santos Nogueira et al., 2003).

263

264 **4. CONCLUSIONS**

265 In this work, we successfully developed a 3D printed VDCs model useful for the evaluation of *in*
266 *vitro* drug release and permeation. The design was in accordance with the pharmacopeia requirement
267 and the dimensions were studied to perfectly fit in a heating block to control the temperature avoiding
268 warm water recirculatory system. As the system has been developed for 3D printing it is possible to
269 continue the personalization based on the needs for example changing or reinventing the donor
270 compartment. The material employed for the manufacturing of the cell (*i.e.*, polypropylene)
271 confirmed its chemical resistance and the possibility to be used to produce leak-free FDM printed
272 objects. Moreover, compared to commercially available VDCs (usually made with glass), the 3D
273 printed VDCs require really low costs of production (less than 2 US \$ of material) and only a few
274 typical lab equipments such as a heating and stirring plate, a heating block and a magnetic stirring
275 bar.

276 VDC *in vitro* testing results fundamental to predict results from *ex vivo* or *in vivo* studies and the
277 possibility to have this testing system readily available in a research lab with a really low cost could
278 increase its diffusion and utilization.

279

280 **AKNOWLEDGEMENTS**

281 The authors acknowledge Fabio De Belvis for the design of the graphical abstract.

282

283 **Funding:** This research received funding from Regione Marche POR MARCHE FESR 2014-2020 -
284 Asse 1 – OS 2 – Azione 2.1 <https://www.marchebiobank.it>.

285

286 **Conflicts of interest:** The authors declare no conflict of interest

287

288 **REFERENCES**

- 289 Boparai, K.S., Singh, R., Singh, H., 2016. Development of rapid tooling using fused deposition modeling: A review.
290 Rapid Prototyp. J. <https://doi.org/10.1108/RPJ-04-2014-0048>
- 291 Capel, A.J., Rimington, R.P., Lewis, M.P., Christie, S.D.R., 2018. 3D printing for chemical, pharmaceutical and
292 biological applications. *Nat. Rev. Chem.* <https://doi.org/10.1038/s41570-018-0058-y>
- 293 César dos Santos Nogueira, C., Mendes Cabral, L., Cristina dos Santos, T., Marucci, A., Alhaique, F., Cabral, L.M.,
294 2003. Evaluation of new polysaccharides networks for extended-release purposes: mesquite seed gum (MSG),
295 xanthan gum and chitosan, *Revista Brasileira de Ciências Farmacêuticas Brazilian Journal of Pharmaceutical*
296 *Sciences.*
- 297 Haq, A., Dorrani, M., Goodyear, B., Joshi, V., Michniak-Kohn, B., 2018a. Membrane properties for permeability
298 testing: Skin versus synthetic membranes. *Int. J. Pharm.* 539, 58–64.
299 <https://doi.org/10.1016/j.ijpharm.2018.01.029>
- 300 Haq, A., Goodyear, B., Ameen, D., Joshi, V., Michniak-Kohn, B., 2018b. Strat-M® synthetic membrane: Permeability
301 comparison to human cadaver skin. *Int. J. Pharm.* 547, 432–437. <https://doi.org/10.1016/j.ijpharm.2018.06.012>
- 302 Herman, A., Herman, A.P., 2012. Caffeine's mechanisms of action and its cosmetic use. *Skin Pharmacol. Physiol.* 26,
303 8–14. <https://doi.org/10.1159/000343174>
- 304 Ilbasmiş Tamer, S., Değim, T., 2007. Passive and iontophoretic delivery of sildenafil through the skin. *Fabad J. Pharm.*
305 *Sci.* 32, 109–119.
- 306 Johal, H.S., Garg, T., Rath, G., Goyal, A.K., 2016. Advanced topical drug delivery system for the management of
307 vaginal candidiasis. *Drug Deliv.* 23, 550–563. <https://doi.org/10.3109/10717544.2014.928760>
- 308 Jung, Y.J., Yoon, J.H., Kang, N.G., Park, S.G., Jeong, S.H., 2012. Diffusion properties of different compounds across
309 various synthetic membranes using Franz-type diffusion cells. *J. Pharm. Investig.* 42, 271–277.
310 <https://doi.org/10.1007/s40005-012-0040-5>
- 311 Kaur, L., Singh, K., Paul, S., Singh, Sukhprit, Singh, Shashank, Jain, S.K., 2018. A Mechanistic Study to Determine the
312 Structural Similarities Between Artificial Membrane Strat-M™ and Biological Membranes and Its Application to
313 Carry Out Skin Permeation Study of Amphotericin B Nanoformulations. *AAPS PharmSciTech* 19, 1606–1624.
314 <https://doi.org/10.1208/s12249-018-0959-6>
- 315 Lim, S.H., Kathuria, H., Tan, J.J.Y., Kang, L., 2018. 3D printed drug delivery and testing systems — a passing fad or
316 the future? *Adv. Drug Deliv. Rev.* 132, 139–168. <https://doi.org/10.1016/j.addr.2018.05.006>
- 317 Marques, M., Ueda, C.T., Shah, V.P., Derdzinski, K., Ewing, G., Flynn, G., Maibach, H., Rytting, H., Shaw, S.,
318 Thakker, K., Yacobi, A., 2009. Topical and transdermal drug products. *Pharmacoepial Forum.*
- 319 Mathew, E., Pitzanti, G., Larrañeta, E., Lamprou, D.A., 2020. Three-dimensional printing of pharmaceuticals and drug
320 delivery devices. *Pharmaceutics.* <https://doi.org/10.3390/pharmaceutics12030266>
- 321 Melocchi, A., Uboldi, M., Cerea, M., Foppoli, A., Maroni, A., Moutaharrik, S., Palugan, L., Zema, L., Gazzaniga, A.,
322 2020. A Graphical Review on the Escalation of Fused Deposition Modeling (FDM) 3D Printing in the
323 Pharmaceutical Field. *J. Pharm. Sci.* <https://doi.org/10.1016/j.xphs.2020.07.011>
- 324 Ng, S.-F., Rouse, J., Sanderson, D., Eccleston, G., 2010. A Comparative Study of Transmembrane Diffusion and
325 Permeation of Ibuprofen across Synthetic Membranes Using Franz Diffusion Cells. *Pharmaceutics* 2, 209–223.
326 <https://doi.org/10.3390/pharmaceutics2020209>
- 327 Ng, S.F., Rouse, J.J., Sanderson, F.D., Eccleston, G.M., 2012. The relevance of polymeric synthetic membranes in
328 topical formulation assessment and drug diffusion study. *Arch. Pharm. Res.* <https://doi.org/10.1007/s12272-012->

329 0401-7
330 Ngo, T.D., Kashani, A., Imbalzano, G., Nguyen, K.T.Q., Hui, D., 2018. Additive manufacturing (3D printing): A
331 review of materials, methods, applications and challenges. *Compos. Part B Eng.*
332 <https://doi.org/10.1016/j.compositesb.2018.02.012>
333 Price, A.J.N., Capel, A.J., Lee, R.J., Pradel, P., Christie, S.D.R., 2020. An open source toolkit for 3D printed fluidics. *J.*
334 *Flow Chem.* 1–15. <https://doi.org/10.1007/s41981-020-00117-2>
335 Romanov, V., Samuel, R., Chaharlang, M., Jafek, A.R., Frost, A., Gale, B.K., 2018. FDM 3D Printing of High-
336 Pressure, Heat-Resistant, Transparent Microfluidic Devices. *Anal. Chem.* 90, 10450–10456.
337 <https://doi.org/10.1021/acs.analchem.8b02356>
338 Siepmann, J., Peppas, N.A., 2011. Higuchi equation: Derivation, applications, use and misuse. *Int. J. Pharm.*
339 <https://doi.org/10.1016/j.ijpharm.2011.03.051>
340 Sil, B.C., Belgrave, R.G., Alvarez, M.P., Luo, L., Cristofoli, M., Penny, M.R., Moore, D.J., Hadgraft, J., Hilton, S.T.,
341 Lane, M.E., 2020. 3D-Printed Franz cells – update on optimization of manufacture and evaluation. *Int. J. Cosmet.*
342 *Sci.* 42, 415–419. <https://doi.org/10.1111/ics.12618>
343 Skelly, J.P., Shah, V.P., Maibach, H.I., 1987. FDA and AAPS report of the workshop on principles and practices of in
344 vitro percutaneous penetration studies: Relevance to bioavailability and bioequivalence. *Pharm. Res.* 4, 265–267.
345 <https://doi.org/10.1023/a:1016428716506>
346 Tiboni, M., Benedetti, S., Skouras, A., Curzi, G., Romano Perinelli, D., Filippo Palmieri, G., Casettari, L., 2020. 3D-
347 printed microfluidic chip for the preparation of glycyrrhetic acid-loaded ethanolic liposomes. *Int. J. Pharm.*
348 119436. <https://doi.org/10.1016/j.ijpharm.2020.119436>
349 Trenfield, S., Basit, A., Goyanes, A., 2020. INNOVATIONS IN 3D: Printed pharmaceuticals. *ONdrugDelivery* 2020,
350 45–49.
351 Uchida, T., Kadhum, W.R., Kanai, S., Todo, H., Oshizaka, T., Sugibayashi, K., 2015. Prediction of skin permeation by
352 chemical compounds using the artificial membrane, Strat-M™. *Eur. J. Pharm. Sci.* 67, 113–118.
353 <https://doi.org/10.1016/j.ejps.2014.11.002>
354